FLT3 and acute myeloid leukemia: Activating mutations in fms-like tyrosine kinase 3 (FLT3) occur in approximately 30% of patients with AML [5, 6], primarily as internal tandem duplication (FLT3-ITD) mutations in the juxtamembrane region (~ 20–25%) and missense point mutations in the tyrosine kinase domain (FLT3-TKD; ~ 5–7%) [5, 7–11].